Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
S. Nandi, P. Kumar, S.A. Amin, T. Jha & S. Gayen. (2021) First molecular modelling report on tri-substituted pyrazolines as phosphodiesterase 5 (PDE5) inhibitors through classical and machine learning based multi-QSAR analysis. SAR and QSAR in Environmental Research 32:11, pages 917-939.
Read now
Read now
Youanna Baselyous, Michael De Cocinis, Mohammed Ibrahim, Alisa Kalra, Rachel Yacoub & Rana Ahmed. (2019) Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA.. Expert Opinion on Drug Safety 18:3, pages 153-161.
Read now
Read now
Jaber Emami, Aida Pourmashhadi, Hojat Sadeghi, Jaleh Varshosaz & Hamed Hamishehkar. (2015) Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy. Pharmaceutical Development and Technology 20:7, pages 791-800.
Read now
Read now
Katerina Antoniou, Michael Malamas & Alexandros A Drosos. (2007) Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opinion on Pharmacotherapy 8:11, pages 1719-1732.
Read now
Read now
Catriona M Turnbull, Adriano G Rossi & Ian L Megson. (2006) Therapeutic effects of nitric oxide-aspirin hybrid drugs. Expert Opinion on Therapeutic Targets 10:6, pages 911-922.
Read now
Read now
Norbert Müller & Markus J Schwarz. (2006) Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders. Expert Review of Neurotherapeutics 6:7, pages 1017-1038.
Read now
Read now
Bernard Bannwarth. (2006) COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?. Expert Opinion on Drug Safety 5:1, pages 1-2.
Read now
Read now
Articles from other publishers (36)
Salah A. Abdel-Aziz, Ehab S. Taher, Ping Lan, Gihan F. Asaad, Hesham A.M. Gomaa, Nawal A. El-Koussi & Bahaa G.M. Youssif. (2021) Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile. Bioorganic Chemistry 111, pages 104890.
Crossref
Crossref
Aya A. Mabrouk, Mina Ibrahim Tadros & Wessam M. El-Refaie. (2021) Improving the efficacy of Cyclooxegenase-2 inhibitors in the management of oral cancer: Insights into the implementation of nanotechnology and mucoadhesion. Journal of Drug Delivery Science and Technology 61, pages 102240.
Crossref
Crossref
Mohammad Abdel-Halim, Heather Tinsley, Adam B. Keeton, Mohammed Weam, Noha H. Atta, Mennatallah A. Hammam, Amr Hefnawy, Rolf W. Hartmann, Matthias Engel, Gary A. Piazza & Ashraf H. Abadi. (2020) Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. Bioorganic Chemistry 104, pages 104322.
Crossref
Crossref
Raj Kumar, Nirjhar Saha, Priyank Purohit, Sanjeev K. Garg, Kapileswar Seth, Vachan S. Meena, Sachin Dubey, Khyati Dave, Rohit Goyal, Shyam S. Sharma, Uttam C. Banerjee & Asit K. Chakraborti. (2019) Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities. European Journal of Medicinal Chemistry 182, pages 111601.
Crossref
Crossref
David Andrew Prince, Ian J Villamagna, Cameron C Hopkins, John R de Bruyn & Elizabeth R Gillies. (2019) Effect of drug loading on the properties of temperature‐responsive polyester–poly(ethylene glycol)–polyester hydrogels. Polymer International 68:6, pages 1074-1083.
Crossref
Crossref
Natalia Tołoczko-Iwaniuk, Dorota Dziemiańczyk-Pakieła, Beata Klaudia Nowaszewska, Katarzyna Celińska-Janowicz & Wojciech Miltyk. (2019) Celecoxib in Cancer Therapy and Prevention – Review. Current Drug Targets 20:3, pages 302-315.
Crossref
Crossref
Jana Martinásková. (2018) Analgetics and pain - what to recommend to the patient in pharmacy and how to advice. Praktické lékárenství 14:4, pages 185-192.
Crossref
Crossref
Martin Anthony Christopher Manoukian, Christopher William Migdal, Amode Ravindra Tembhekar, Jerad Alexander Harris & Charles DeMesa. (2017) Topical Administration of Ibuprofen for Injured Athletes: Considerations, Formulations, and Comparison to Oral Delivery. Sports Medicine - Open 3:1.
Crossref
Crossref
Maarten Janssen, Ufuk Tan Timur, Nina Woike, Tim J.M. Welting, Guy Draaisma, Marion Gijbels, Lodewijk W. van Rhijn, George Mihov, Jens Thies & Pieter J. Emans. (2016) Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection. Journal of Controlled Release 244, pages 30-40.
Crossref
Crossref
Joseph V PergolizziJrJr, Robert B Raffa, Srinivas Nalamachu & Robert TaylorJrJr. (2016) Evolution to low-dose NSAID therapy. Pain Management 6:2, pages 175-189.
Crossref
Crossref
Chi Zhang, Fan Wang, Yingxia Zhang, Yimin Kang, Haisheng Wang, Mingming Si, Liping Su, Xue Xin, Feng Xue, Fei Hao, Lechu Yu, Jinzhong Xu, Yanlong Liu & Mingming Xue. (2015) Celecoxib prevents pressure overload‐induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress. Journal of Cellular and Molecular Medicine 20:1, pages 116-127.
Crossref
Crossref
Audrey Petit, Everaldo M. Redout, Chris H. van de Lest, Janny C. de Grauw, Benno Müller, Ronald Meyboom, Paul van Midwoud, Tina Vermonden, Wim E. Hennink & P. René van Weeren. (2015) Sustained intra-articular release of celecoxib from in situ forming gels made of acetyl-capped PCLA-PEG-PCLA triblock copolymers in horses. Biomaterials 53, pages 426-436.
Crossref
Crossref
Paul J. Limburg, Sumithra J. Mandrekar, Marie Christine Aubry, Katie L. Allen Ziegler, Jun Zhang, Joanne E. Yi, Michael Henry, Henry D. Tazelaar, Stephen Lam, Annette McWilliams, David E. Midthun, Eric S. Edell, Otis B. Rickman, Peter Mazzone, Melvyn Tockman, John F. Beamis, Carla Lamb, Michael Simoff, Charles Loprinzi, Eva Szabo & James Jett. (2013) Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer 79:3, pages 254-261.
Crossref
Crossref
Sai Kiran Sharma, Baker Jawabrah Al-Hourani, Melinda Wuest, Jonathan Y. Mane, Jack Tuszynski, Vickie Baracos, Mavanur Suresh & Frank Wuest. (2012) Synthesis and evaluation of fluorobenzoylated di- and tripeptides as inhibitors of cyclooxygenase-2 (COX-2). Bioorganic & Medicinal Chemistry 20:7, pages 2221-2226.
Crossref
Crossref
Elmar Friderichs, Thomas Christoph & Helmut Buschmann. 2003. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
Robert W. Hurley & Christopher L. Wu. 2010. Miller's Anesthesia. Miller's Anesthesia
2757
2781
.
Marie N. Hanna, Jamie D. Murphy, Kanupriya Kumar & Christopher L. Wu. (2009) Postoperative Pain Management in the Elderly Undergoing Thoracic Surgery. Thoracic Surgery Clinics 19:3, pages 353-361.
Crossref
Crossref
R. Longo, F. Cacciamani, G. Naso & G. Gasparini. (2008) Pancreatic cancer: From molecular signature to target therapy. Critical Reviews in Oncology/Hematology 68:3, pages 197-211.
Crossref
Crossref
Jian WANG, Yu Qian SHI, Jing YI, Shuang YE, Li Min WANG, Yan Ping XU, Min HE & Xian Ming KONG. (2008) Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference. Journal of Digestive Diseases 9:4, pages 228-237.
Crossref
Crossref
Bruce E. Rapuano, Roosevelt Boursiquot, Emre Tomin, Daniel E. MacDonald, Surekha Maddula, Deepak Raghavan, Joseph M. Lane & David L. Helfet. (2007) The effects of COX-1 and COX-2 inhibitors on prostaglandin synthesis and the formation of heterotopic bone in a rat model. Archives of Orthopaedic and Trauma Surgery 128:3, pages 333-344.
Crossref
Crossref
Shigeru Ushiyama, Tomoko Yamada, Yukiko Murakami, Sei-ichiro Kumakura, Shin-ichi Inoue, Keisuke Suzuki, Akira Nakao, Akihiro Kawara & Tomio Kimura. (2008) Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. European Journal of Pharmacology 578:1, pages 76-86.
Crossref
Crossref
Hanno Riess. 2008. Pancreatic Cancer. Pancreatic Cancer
123
129
.
Elmar Friderichs, Thomas Christoph & Helmut Buschmann. 2000. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry.
Li-Chia Chen & Darren M Ashcroft. (2007) Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials. Pharmacoepidemiology and Drug Safety 16:7, pages 762-772.
Crossref
Crossref
V. Benetello, F.C. Sakamoto, F.P.M. Giglio, V.T. Sakai, A.M. Calvo, K.C.S. Modena, B.L. Colombini, T.J. Dionísio, J.R.P. Lauris, F.A.C. Faria & C.F. Santos. (2007) The selective and non-selective cyclooxygenase inhibitors valdecoxib and piroxicam induce the same postoperative analgesia and control of trismus and swelling after lower third molar removal. Brazilian Journal of Medical and Biological Research 40:8, pages 1133-1140.
Crossref
Crossref
Vaqar Mustafa Adhami, Arshi Malik, Najia Zaman, Sami Sarfaraz, Imtiaz Ahmad Siddiqui, Deeba Nadeem Syed, Farrukh Afaq, Farrukh Sierre Pasha, Mohammad Saleem & Hasan Mukhtar. (2007)
Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both
In vitro
and
In vivo
. Clinical Cancer Research 13:5, pages 1611-1619.
Crossref
Crossref
Cristiana Griffoni, Enzo Spisni, Antonio Strillacci, Mattia Toni, Markus Michael Bachschmid & Vittorio Tomasi. (2007) Selective inhibition of prostacyclin synthase activity by rofecoxib. Journal of Cellular and Molecular Medicine 11:2, pages 327-338.
Crossref
Crossref
Daniel J. Salzberg & Matthew R. Weir. 2007. Inflammation in the Pathogenesis of Chronic Diseases. Inflammation in the Pathogenesis of Chronic Diseases
159
174
.
L-C. Chen & D. M. Ashcroft. (2006) Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 31:6, pages 565-576.
Crossref
Crossref
Todd P. Stitik, Eric Altschuler & Patrick M. Foye. (2006) Pharmacotherapy of Osteoarthritis. American Journal of Physical Medicine & Rehabilitation 85:Supplement, pages S15-S28.
Crossref
Crossref
PATRICIA O'MALLEY. (2006) The Emerging Cardiovascular Risk Profile for Nonsteroidal Anti-inflammatory Drugs. Clinical Nurse Specialist 20:6, pages 277-265.
Crossref
Crossref
James M Brophy. (2006) Vascular events with selective COX2 inhibitors and NSAIDs: analyzing the risks. Nature Clinical Practice Cardiovascular Medicine 3:11, pages 586-587.
Crossref
Crossref
Muhammad Wasif Saif, Aymen Elfiky & Robert Diasio. (2006) Hand-Foot Syndrome Variant in a Dihydropyrimidine Dehydrogenase–Deficient Patient Treated with Capecitabine. Clinical Colorectal Cancer 6:3, pages 219-223.
Crossref
Crossref
Francesco Dentali, James D Douketis, Karen Woods, Lehana Thabane, Gary Foster, Anne Holbrook & Mark Crowther. (2016) Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized, Double-Blind, Controlled Trial. Annals of Pharmacotherapy 40:7-8, pages 1241-1247.
Crossref
Crossref
Pascal-André Vendittoli, Patrice Makinen, Pierre Drolet, Martin Lavigne, Michel Fallaha, Marie-Claude Guertin & France Varin. (2006) A Multimodal Analgesia Protocol for Total Knee Arthroplasty. The Journal of Bone & Joint Surgery 88:2, pages 282-289.
Crossref
Crossref
PASCAL-ANDRE VENDITTOLI, PATRICE MAKINEN, PIERRE DROLET, MARTIN LAVIGNE, MICHEL FALLAHA, MARIE-CLAUDE GUERTIN & FRANCE VARIN. (2006) A MULTIMODAL ANALGESIA PROTOCOL FOR TOTAL KNEE ARTHROPLASTY. The Journal of Bone and Joint Surgery-American Volume 88:2, pages 282-289.
Crossref
Crossref